Lundbeck to acquire Prexton Therapeutics, participated by Ysios Capital, in a deal valued at up to €905 million

by Ysios Capital

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) have announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck wil...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Fellow Funders Introduces Alboris Mancha...

by Fellow Funders

Fellow Funders has announced the launch of Alboris Mancha Sextus, a ne...

Photos Stream